Betterlife Pharma Inc. (TSE:BETR) has released an update.
BetterLife Pharma Inc. has successfully secured $1.168 million through convertible debentures to propel the advancement of its non-hallucinogenic LSD-based drug, BETR-001, targeting mental disorders like GAD and MDD. The company emphasizes BETR-001’s potential to offer the therapeutic benefits of LSD without associated side effects, envisioning patient self-administration and broader access. This funding round includes significant investment from insiders, aligning with regulatory exemptions and showcasing the commitment of BetterLife’s leadership to its innovative treatments.
For further insights into TSE:BETR stock, check out TipRanks’ Stock Analysis page.
